Edition:
United States

MEI Pharma Inc (MEIP.OQ)

MEIP.OQ on NASDAQ Stock Exchange Capital Market

3.13USD
25 May 2018
Change (% chg)

$-0.03 (-0.95%)
Prev Close
$3.16
Open
$3.18
Day's High
$3.35
Day's Low
$3.08
Volume
60,086
Avg. Vol
40,630
52-wk High
$3.55
52-wk Low
$1.78

Latest Key Developments (Source: Significant Developments)

Caxton Reports 9.1% Passive Stake In Mei Pharma
Friday, 25 May 2018 06:23am EDT 

May 25 (Reuters) - MEI Pharma Inc ::CAXTON CORPORATION REPORTS 9.1 PERCENT PASSIVE STAKE IN MEI PHARMA INC AS OF MAY 16, 2018 - SEC FILING.  Full Article

Growth Equity Opportunities Fund V LLC Reports 9.99 Pct Stake In MEI Pharma Inc
Wednesday, 23 May 2018 04:21pm EDT 

May 23 (Reuters) - MEI Pharma Inc ::GROWTH EQUITY OPPORTUNITIES FUND V LLC REPORTS 9.99 PERCENT STAKE IN MEI PHARMA INC AS OF MAY 16 - SEC FILING.  Full Article

MEI Pharma Says Interim Data Review Supports Continuation Of ME-344 Clinical Study
Tuesday, 13 Feb 2018 08:00am EST 

Feb 13 (Reuters) - MEI Pharma Inc ::MEI PHARMA INTERIM DATA REVIEW SUPPORTS CONTINUATION OF CLINICAL STUDY EVALUATING ME-344 IN PATIENTS WITH BREAST CANCER.MEI PHARMA INC - INTERIM STUDY DATA SHOW THAT ME-344 WAS GENERALLY WELL-TOLERATED.MEI PHARMA - BASED ON INTERIM STUDY RESULTS, IT WAS DETERMINED THAT COMPLETING ENROLLMENT OF STUDY OF ME-344 IN COMBINATION WITH BEVACIZUMAB IS WARRANTED.  Full Article

MEI Pharma Q2 Loss Per Share $0.16
Thursday, 8 Feb 2018 08:00am EST 

Feb 8 (Reuters) - MEI Pharma Inc ::MEI PHARMA REPORTS SECOND QUARTER FISCAL YEAR 2018 RESULTS.Q2 LOSS PER SHARE $0.16.‍AS OF DECEMBER 31, 2017, HAD $42.4 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS, WITH NO OUTSTANDING DEBT​.‍BELIEVES CASH POSITION WILL BE SUFFICIENT TO FUND OPERATIONS INTO CALENDAR YEAR 2019​.  Full Article

Helsinn Group and MEI Pharma's Pracinostat receives orphan drug designation from European Medicines Agency
Thursday, 11 Jan 2018 03:00am EST 

Jan 11 (Reuters) - Mei Pharma Inc ::HELSINN GROUP AND MEI PHARMA ANNOUNCE THAT PRACINOSTAT HAS RECEIVED ORPHAN DRUG DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML).  Full Article

MEI Pharma Announces FDA Clearance Of Investigational New Drug Application For CDK Inhibitor Voruciclib
Monday, 8 Jan 2018 09:00am EST 

Jan 8 (Reuters) - MEI Pharma Inc ::MEI PHARMA ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CDK INHIBITOR VORUCICLIB.MEI PHARMA INC - LOOK FORWARD TO ADVANCING VORUCICLIB THROUGH CLINIC IN Q2 OF 2018.  Full Article

Mei Pharma enters into at-market equity offering sales agreement
Wednesday, 8 Nov 2017 08:48am EST 

Nov 8 (Reuters) - Mei Pharma Inc :On Nov. 8, 2017, co entered into at--market equity offering sales agreement with Stifel, Nicolaus & Company, Incorporated, as sales agent​.Pursuant to sales agreement co may sell, from time to time, an aggregate of up to $30 million of common stock - SEC filing.  Full Article

Mei Pharma announces exclusive license agreement with Presage Biosciences for voruciclib
Tuesday, 5 Sep 2017 04:05pm EDT 

Sept 5 (Reuters) - Mei Pharma Inc :Mei Pharma announces exclusive license agreement with Presage Biosciences for voruciclib, an oral, selective cdk inhibitor.Mei Pharma Inc - ‍Presage will receive near-term payments of $2.9 million​.Mei Pharma Inc - ‍Presage will also receive mid-single-digit tiered royalties on net sales of any product successfully developed​.  Full Article

Mei Pharma says one patient in ME-401 study experienced grade 3 neutropenia
Wednesday, 31 May 2017 08:30am EDT 

May 31 (Reuters) - Mei Pharma Inc ::Mei Pharma announces pre-specified response rate exceeded in dose-escalation study of ME-401 in chronic lymphocytic leukemia and follicular lymphoma.Mei Pharma -independent safety review committee finds no dose limiting toxicities, declares minimum biologically effective dose, recommends dose escalation.Mei Pharma Inc says there have been no reports of ALT/AST elevations, colitis or pneumonitis, events commonly reported with other drugs in the class.Mei Pharma Inc says one patient in study experienced grade 3 neutropenia that was considered related to study drug.  Full Article

MEI Pharma Inc files for mixed shelf of up to $150 million
Thursday, 4 May 2017 09:26am EDT 

May 4 (Reuters) - MEI Pharma Inc : :MEI Pharma Inc files for mixed shelf of up to $150 million .  Full Article

BRIEF-Growth Equity Opportunities Fund V LLC Reports 9.99 Pct Stake In MEI Pharma Inc

* GROWTH EQUITY OPPORTUNITIES FUND V LLC REPORTS 9.99 PERCENT STAKE IN MEI PHARMA INC AS OF MAY 16 - SEC FILING Source text: (https://bit.ly/2IHP4lE) Further company coverage: